Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells

Anticancer Research

Volumn 34, Issue 10, 2014, Pages 5487-5494

  Yamauchi, Takahiro ^a   Uzui, Kanako ^a   Nishi, Rie ^a   Shigemi, Hiroko ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Acute myeloid leukemia; DNA repair; Gemtuzumab ozogamicin; HL 60 cells; Olaparib

Indexed keywords

CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; OLAPARIB; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; HL 60 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MYELOID LEUKEMIA; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; TOXICITY;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84917695041     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Sievers EL and Linenberger M: Mylotarg antibody-targeted chemotherapy comes of age. Curr Opin Oncol 13: 522-527, 2001.
2. Bernstein ID, Singer JW, Andrews RG, Keating A, Powell JS, Bjornson BH, Cuttner J, Najfeld V, Reaman G and Raskind W: Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Investig 79: 1153-1159, 1987.
3. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, and Pazdur R: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7: 1490-1496, 2001.
4. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, and Bernstein ID: Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98: 988-994, 2001.
5. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, and Linenberger ML: Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 102: 1466-1473, 2003.
6. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, Bernstein ID and Appelbaum FR: CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 109: 4168-4170, 2007.
7. Ikemoto N, Kumar RA, Ling TT, Ellestad GA, Danishefsky SJ and Patel DJ: Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc Natl Acad Sci USA 92: 10506-10510, 1995.
8. Elmroth K, Nygren J, Ma˚rtensson S, Ismail H and Hammarsten O: Cleavage of cellular DNA by calicheamicin γ1. DNA Repair 2: 363-374, 2003.
9. Duong HK and Sekeres MA: Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging 4: 197-205, 2009.
10. Yamauchi T, Matsuda Y, Tasaki T, Negoro E, Ikegaya S, Takagi K, Yoshida A, Urasaki Y and Ueda T: The induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells. Cancer Sci 103: 1722-1729, 2012.
11. Dedon PC, Salzberg AA and Xu J: Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry 32: 3617-3622, 1993.
12. Bolderson E, Richard DJ, Zhou B-B S and Khanna KK: Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair. Clin Cancer Res 15: 6314-6320, 2009.
13. Hartlerode AJ and Scully R: Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J 423: 157-168, 2010.
14. Rassool FV and Tomkinson AE: Targeting abnormal DNA double strand break repair in cancer. Cell Mol Life Sci 67: 3699-3710, 2010.
15. Iyama T and Wilson DM 3rd: DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst) 12: 620-636, 2013.
16. Wang Z, Wang F, Tang T and Guo C: The role of PARP1 in the DNA damage response and its application in tumor therapy. Front Med 6: 156-164, 2012.
17. Shall S and de Murcia G: Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 460: 1-15, 2000.
18. Hollander MC and Fornace AJ Jr.: Genomic instability, centrosome amplification, cell cycle checkpoints and Gadd45a. Oncogene 21: 6228-6233, 2002.
19. Audebert M, Salles B and Calsou P: Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 279: 55117-55126, 2004.
20. De Vos M, Schreiber V and Dantzer F: The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 84: 137-146, 2012.
21. Yamauchi T, Uzui K, Shigemi H, Negoro E, Yoshida A and Ueda T: Aurora B inhibitor barasertib and cytarabine in combination exert greater-than-additive cytotoxicity against cytarabine-resistant acute myeloid leukemia cells. Cancer Sci 104: 926-933, 2013.
22. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul 22: 27-55, 1984.
23. Hühn D, Bolck HA, and Sartori AA: Targeting DNA double-strand break signaling and repair: recent advances in cancer therapy. Swiss Med Wkly 143: w13837, 2013.
24. Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, and Appelbaum FR: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104: 1442-1452, 2005.
25. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, Walter RB, Tallman MS, Stenke L and Appelbaum FR: A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121: 4854-4860, 2013.
26. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, Yin JA, Hunter A, Goldstone AH and Wheatley K: Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 29: 369-377, 2011.
27. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S and Dombret H; Acute Leukemia French Association: Effect of gemtuzumab ozogamicin on survival of adult patients with denovo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379: 1508-1516, 2012.
28. Krempler A, Deckbar D, Jeggo PA and Löbrich M: An imperfect G2M checkpoint contributes to chromosome instability following irradiation of S and G2 phase cells. Cell Cycle 6: 1682-1686, 2007.
29. Ciccia A and Elledge SJ: The DNA damage response: making it safe to play with knives. Mol Cell 40: 179-204, 2010.
30. Ariumi Y, Masutani M, Copeland TD, Mimori T, Sugimura T, Shimotohno K, Ueda K, Hatanaka M and Noda M: Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent protein kinase in vitro. Oncogene 18: 4616-4625, 1999.
31. Galande S and Kohwi-Shigematsu T: Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences. J Biol Chem 274: 20521-20528, 1999.
32. Haince JF, Kozlov S, Dawson VL, Dawson TM, Hendzel MJ, Lavin MF and Poirier GG: Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA damaging agents. J Biol Chem 282: 16441-16453, 2007.
33. Haince JF, McDonald D, Rodrigue A, Déry U, Masson JY, Hendzel MJ and Poirier GG: PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem 283: 1197-1208, 2008.
34. Hosoya N and Miyagawa K: Targeting DNA damage response in cancer therapy. Cancer Sci 105: 370-388, 2014.